The FDA approved Gilead's request to grant orphan drug status to remdesivir, an antiviral that is being tested in people with COVID-19, the disease caused by the novel coronavirus. Orphan drugs that are approved get breaks on taxes and fees and get seven years' market exclusivity.
FDA grants orphan drug status to remdesivir for COVID-19
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.